{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"-Death that results from a transplant procedure-related complication (e.g. infection, organ failure, hemorrhage, GVHD) rather than from relapse of the underlying disease or an unrelated cause","groups":[{"description":"* Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy\n* Stem cell transplantation on Day 0\n* Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently\n* To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.","id":"OG000","title":"Pilot Study: Itacitinib"},{"description":"* Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy\n* Stem cell transplantation on Day 0\n* Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently","id":"OG001","title":"Expansion Phase: Itacitinib"},{"description":"-Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.","id":"OG002","title":"Donors"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Donors were not evaluable for this outcome measure. There were 2 participants in the Pilot Study and 2 participants in the Expansion Phase who were not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 180","title":"Number of Participants With Treatment Related Mortality","type":"SECONDARY","unitOfMeasure":"Participants"}